Efficacy of Postbiotic Supplementation in Improving Antioxidant Status
Effects of Postbiotic Supplementation in Improving Total Antioxidant Status in Healthy Adults
This study will evaluate changes in salivary antioxidant capacity, oxidative stress biomarkers, and self-perceived general well-being during eight weeks of postbiotic supplementation in generally healthy adults.
Thirty-six participants aged 18 years or older will receive MettaBion Liquid twice daily for eight weeks. Assessments will be conducted before supplementation and at Weeks 4 and 8. Saliva samples will be analysed for total antioxidant capacity, malondialdehyde, 3-nitrotyrosine, and 8-hydroxy-2'-deoxyguanosine. General well-being will be assessed using a visual analogue scale.
This prospective, single-arm study will estimate within-participant changes and their variability to inform the design and sample-size planning of a future randomised, placebo-controlled trial.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
This prospective, single-arm, open-label study will evaluate changes in salivary antioxidant capacity, oxidative stress biomarkers, and self-perceived general well-being following eight weeks of postbiotic supplementation in generally healthy adults. The study will recruit 36 participants aged 18 years or older. Assessments will be conducted at baseline, Week 4, and Week 8.
Participants will consume MettaBion Liquid orally for eight weeks, taking one sachet after breakfast and one sachet after dinner each day. Each sachet contains 5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum, providing a total daily intake of 10,000 mg of the preparation. Adherence will be monitored using a participant compliance form.
Unstimulated saliva samples will be collected at each assessment visit to measure total antioxidant capacity (T-AOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) using Elabscience assay kits. These measurements will assess antioxidant capacity and markers of lipid peroxidation, protein nitration, and oxidative DNA damage, respectively. Participants will also assess their general well-being using a visual analogue scale ranging from 1 to 10, with higher scores indicating better perceived well-being.
The primary outcome will be the change in salivary T-AOC from baseline to Week 8. Secondary outcomes will include the change in salivary T-AOC from baseline to Week 4 and changes in salivary MDA, 3-NT, 8-OHdG, and general well-being scores from baseline to Weeks 4 and 8.
Eligible participants must be generally healthy, willing to follow the study procedures and attend follow-up visits, and able to provide written informed consent before enrolment. Individuals will be excluded if they are currently taking supplements intended to improve antioxidant status, antibiotics, antiviral medicines, or prebiotic or postbiotic supplements; have undergone major surgery within the preceding six months; or are pregnant or breastfeeding.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Chung Keat Tan, PhD
- Telefoonnummer: +6017-5063305
- E-mail: cktan.jsci@gmail.com
Studie Locaties
-
-
Kuala Lumpur
-
Cheras, Kuala Lumpur, Maleisië, 56000
- UCSI University
-
Contact:
- Eugenie Sin Sing Tan, PhD
- Telefoonnummer: +6016-8924008
- E-mail: eugenietan@ucsiuniversity.edu.my
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Generally healthy adults aged 18 years or older.
- Willing to follow the study plan and attend follow-up visits.
- Willing to provide written informed consent before enrolment.
Exclusion Criteria:
- Currently taking supplements intended to improve antioxidant status.
- Currently taking antibiotics or antiviral medicines.
- Currently taking prebiotic or postbiotic supplements.
- Major surgery within the previous six months.
- Pregnant or breastfeeding.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: MettaBion Liquid Supplementation
Participants will consume one sachet of MettaBion Liquid after breakfast and one sachet after dinner daily for eight weeks. Each sachet contains 5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum. |
5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in salivary total antioxidant capacity from baseline to Week 8
Tijdsspanne: Baseline and Week 8
|
Change in salivary total antioxidant capacity measured using an Elabscience assay kit. |
Baseline and Week 8
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in salivary malondialdehyde
Tijdsspanne: Baseline and Week 8
|
Change in salivary malondialdehyde, a marker of lipid peroxidation, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Change in salivary 3-nitrotyrosine
Tijdsspanne: Baseline and Week 8
|
Change in salivary 3-nitrotyrosine, a marker of protein nitration, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Salivary 8-hydroxy-2'-deoxyguanosine (8-OHdG)
Tijdsspanne: Baseline and Week 8
|
Change in salivary 8-hydroxy-2'-deoxyguanosine, a marker of oxidative DNA damage, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Self-perceived general well-being
Tijdsspanne: Baseline, Week 4, and Week 8
|
Change in self-perceived general well-being assessed using a visual analogue scale ranging from 1 to 10, with higher scores indicating better general well-being. |
Baseline, Week 4, and Week 8
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
Andere studie-ID-nummers
- METTABION - ANTIOXIDANT
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified individual participant data underlying the published results will be made available to qualified researchers upon reasonable request to the principal investigator. Access will be subject to review of the proposed research purpose, consistency with participant consent and institutional ethics requirements, and a signed data use agreement.
IPD-tijdsbestek voor delen
Beginning six months after publication of the study results and continuing for five years.
IPD-toegangscriteria voor delen
Researchers must submit a methodologically sound proposal outlining the intended use of the data to the principal investigator.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .